Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mangoceuticals Q3 2026 Results: Net Loss of $3.55M, Loss Narrows

Mangoceuticals, Inc. is a smaller reporting company and emerging growth company focused on scaling its operations and marketing its products. The filing highlights significant risks including a limited operating history, the need for additional funding, and reliance on third-party compounding pharmacies for products not approved by the FDA.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.1
Gross profit0.00.1
Profit before tax-3.6-7.6
Net income-3.6-7.6
EPS (diluted, $ a share)$-0.19$-0.69

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-17.5%
Gross margin55.2%
Source

10-Q filed with the SEC, NASDAQ: MGRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mangoceuticals, Inc.: key numbers

Share price
$0.1603Close, Nov 16
Market cap
$3.46M
Shares outstanding
21.57MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Misc Health & Allied Services, NECSIC 8090

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mangoceuticals, Inc.

All →
5:25 PM ET 8-K
Other 8-K Filing

Mangoceuticals Other 8-K Filing

Mangoceuticals amended its Series B and Series C preferred stock designations and established a new Series D Preferred Stock class. The Series D Preferred Stock will rank senior to common stock and existing preferred classes regarding dividends and liquidation, though no shares were issued at the time of filing. The amendments include waivers from existing preferred holders to allow for the senior ranking and future Series D transactions.

5:25 PM ET 8-K
Capital Raise

Mangoceuticals Capital Raise

Mangoceuticals, Inc. received written consent from its Series B Preferred Stock holder to establish a new series of 8% Series D Convertible Cumulative Preferred Stock. The company plans to offer up to 1,000,000 shares of the Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B holder also approved an amendment to recognize the senior dividend and liquidation rights of the new Series D shares.

4:02 PM ET 8-K
Capital Raise

Mangoceuticals Capital Raise

Mangoceuticals, Inc. entered into a securities purchase agreement for a registered direct offering of 657,000 shares of common stock and accompanying warrants to purchase up to 657,000 additional shares. The offering was priced at $0.75 per unit, representing a 74% premium to the recent market close, and is expected to generate gross proceeds of approximately $492,750 for working capital and general corporate purposes.

Counterparty
certain investors
3:51 PM ET 8-K
Divestiture

Mangoceuticals Divestiture to Two accredited investors for $2.5M

Mangoceuticals, Inc. sold a 25% ownership stake in its subsidiary, MangoRx IP Holdings, LLC, to two accredited investors for $2.5 million. The transaction was structured at the subsidiary level to raise capital for the commercialization of its antiviral technology (MGX-0024) without diluting the parent company's common stock.

Value
$2.5M
Counterparty
Two accredited investors

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.